A phase II study of intensive chemotheraphy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes

Hematology Journal

Volumn 5, Issue 3, 2004, Pages 209-215

  Prébet, Thomas ^a   Ducastelle, Sophie ^a   Debotton, Stephan ^b   Stamatoullas, Aspasia ^c   Deconinck, Eric ^d   Fruchart, Christophe ^e   Gratecos, Nicole ^f   Ifrah, Norbert ^g   Dreyfus, Français ^h   Fenaux, Pierre ⁱ   Wattel, Eric ^a,j  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e LE HAVRE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h NONE   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j CENTRE LÉON BÉRARD   (France)

more..

Author keywords

Fludarabine; Intensive chemotherapy; Myelodysplastic syndromes

Indexed keywords

CORTICOSTEROID; CYTARABINE; FLUDARABINE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; AGE; AGED; ALLOGRAFT; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; KARYOTYPE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; MYELODYSPLASTIC SYNDROMES; P-GLYCOPROTEIN; SURVIVAL ANALYSIS; TIME FACTORS; VIDARABINE;

EID: 3142766952     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200363     Document Type: Article

References (63)

1. Fenaux P. Myelodysplastic syndromes. Hematol Cell Ther 1996; 38: 363-380.
2. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425-433.
3. Oscier DG. Myelodysplastic syndromes. Baillieres Clin Haematol 1987; 1: 389-426.
4. Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-226.
5. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-2331.
6. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 1996; 88: 358-365.
7. Yakoub-Agha I, de La Salmoniere P, Ribaud P, Sutton L, Wattel E, Kuentz M et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients - report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18: 963-971.
8. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-1864.
9. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992; 65: 162-168.
10. Hellstrom E, Robert KH, Gahrton G, Mellstedt H, Lindemalm C, Einhorn S et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol 1988; 40: 449-459.
11. Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia 1999; 13: 524-529.
12. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015-1024.
13. Wattel E, De Botton S, Luc Lai J, Preudhomme C, Lepelley P, Bauters F et al. Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders. Br J Haematol 1997; 98: 983-991.
14. Poulain S, Lepelley P, Preudhomme C, Cambier N, Cornillon J, Wattel E et al. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 2000; 110: 591-598.
15. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65: 1364-1372.
16. Hoyle CF, de Bastos M, Wheatley K, Sherrington PD, Fischer PJ, Rees JK et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72: 45-53.
17. Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989; 7: 1637-1645.
18. Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Miclea JM et al. Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Reflexion en Hematologie. Leukemia 1997; 11: 16-21.
19. Wattel E, Hecquet B, Grahek D, Hebbar M, Morel P, Lai JL et al. Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. Leuk Res 1993; 17: 733-739.
20. De Witte T, Muus P, De Pauw B, Haanen C. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years. Bone Marrow Transplant 1989; 4 (Suppl 3):33-35.
21. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 1990; 66: 831-837.
22. De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 1997; 90: 3853-3857.
23. Estey E, Pierce S, Kantarjian H, O'Brien S, Beran M, Andreeff M et al. Treatment of myelodysplastic syndromes with AML-type chemotherapy. Leuk Lymphoma 1993; 11(Suppl 2): 59-63.
24. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/-all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478-2484.
25. Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 1999; 86: 2006-2013.
26. Hamblin TJ. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev 1992; 6: 215-219.
27. Hasle H, Kerndrup G, Yssing M, Clausen N, Ostergaard E, Jacobsen N et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996; 10: 1269-1273.
28. Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C et al. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Haematologica 1997; 82: 9-12.
29. Martiat P, Ferrant A, Michaux JL, Sokal G. Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematol Oncol 1988; 6: 299-305.
30. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910-1917.
31. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315-1323.
32. Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994; 8: 998-1004.
33. Carella AM, Cascavilla N, Greco MM, Melillo L, Sajeva MR, Ladogana S et al. Treatment of 'poor risk' acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma 2001; 40: 295-303.
34. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 513-520.
35. Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma 2001; 40: 305-313.
36. de la Rubia J, Regadera A, Martin G, Cervera J, Sanz G, Martinez J et al. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res 2002; 26: 725-730.
37. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98: 3575-3583.
38. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102: 647-655.
39. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99: 939-944.
40. Russo D, Candoni A, Grattoni R, Bertone A, Zaja F. Fludarabine and cytosine-arabino side for poor-risk acute myeloid leukemia. Haematologica 1998; 83: 281-282.
41. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H et al. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed /refractory acute myelogenous leukemia. Leukemia 2003; 17: 990-993.
42. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 1994; 8: 1842-1846.
43. Nokes TJ, Johnson S, Harvey D, Goldstone AH. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma 1997; 27: 93-101.
44. Avramis VI, Nandy P, Kwock R, Solorzano MM, Mukherjee SK, Danenberg P et al. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 1998; 18: 2327-2338.
45. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W et al. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin Cancer Res 1998; 4: 45-52.
46. Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 2002; 20: 4217-4224.
47. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
48. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972; 135: 185-206.
49. Cox DR. Regression models and life-tables (with discussions), Series B. J R Stat Soc 1972; 34: 187-220.
50. Estey EH. Prognostic factors in acute myelogenous leukemia. Leukemia 2001; 15: 670-672.
51. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
52. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ et al. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 2001; 92: 1999-2015.
53. Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B et al. IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF) - an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study. Klin Padiatr 1996; 208: 229-235.
54. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671-678.
55. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Hematol 2000; 72: 139-150.
56. Ruutu T, Hanninen A, Jarventie G, Koistinen P, Koivunen E, Katka K et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 1997; 21: 133-138.
57. Pogliani EM, Baldicchi L, Pioltelli P, Miccolis IR, Mangiagalli M, Corneo GM. Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML). Leuk Lymphoma 1995; 19: 473-477.
58. Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 2003; 17: 859-868.
59. Okamoto T, Kanamaru A, Shimazaki C, Motoji T, Takemoto Y, Takahashi M et al. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis. Int J Hematol 2000; 72: 200-205.
60. Larson RA. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia 1996; 10(Suppl 1): S23-S25.
61. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-344.
62. Di Raimondo F, Giustolisi R, Cacciola E, O'Brien S, Kantarjian H, Robertson LB et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11: 63-68.
63. Byrd JC, Hertler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 1995; 6: 300-301.